Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
NVO is expanding manufacturing, advancing next-generation therapies like CagriSema, and leveraging price leadership and direct-to-consumer channels. With a forward P/E of 11–15x, NVO trades at a deep discount to peers and historical averages, despite strong fundamentals and growth prospects. I rate NVO a Buy, with a base-case 2030 price target of $135–$165, supported by stable insulin/GLP-1 franchises and strategic execution. Woman using a Semaglutide injection pen. Munro/E+ via Getty Images Investment Thesis Conventional wisdom increasingly frames Novo Nordisk A/S ( NVO ) as the loser in its battle with Eli Lilly and Company ( LLY ) for the obesity drug market. I think that's wrong. The analogy here isn't Netflix versus Blockbuster, where one This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NOVO:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Vaxess Technologies raises $50m, rebrands to Terrestrial Bio [Yahoo! Finance]Yahoo! Finance
- Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? [Yahoo! Finance]Yahoo! Finance
- Hims & Hers shifts business model after Novo deal [Yahoo! Finance]Yahoo! Finance
- FDA Approval Of Awiqli Adds New Dimension To Novo Nordisk Story [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/26/26 - Form 6-K
- NVO's page on the SEC website